Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis
NCT05511766Phase 3Completed
- Sponsor
- Tanta University
- Start
- Nov 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in Cirrhosis comparing PLACEBO, Allopurinol and Atorvastatin (3 arms). Primary endpoint: Recurrence number at 6 months. Started Nov 2022; status: completed.
02
Drugs
allopurinolatorvastatin
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on NCT05511766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05511766.